Nevanac®
Nepafenac is a prodrug NSAID that is bioactivated in ocular tissues. Used for pain and inflammation associated with cataract surgery.
| Dosage Form | Ophthalmic Suspension |
| Strength | 0.1%, 0.3% |
| Storage | Store at 2–25°C. |
| Category | Ophthalmics |
| Availability | Available for Transfer |
Postoperative pain and inflammation associated with cataract surgery; prevention of macular edema after cataract surgery in diabetic patients.
Prodrug rapidly converted by intraocular hydrolases to amfenac, a potent COX inhibitor. Bioactivation within the eye provides targeted anti-inflammatory activity with reduced systemic exposure.
Each Burrard Pharmaceuticals technology transfer package for Nepafenac includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.